Session Information
ASRM 65th Annual Meeting
Click here to go to the previous page
Contemporary Understanding and Treatment of Fibroids to Optimize Pregnancy Outcome
Track
:
PG Track Three
Program Code:
PG06
Date:
Saturday, October 17, 2009
Time:
8:15 AM to 5:00 PM
EST
Location:
C108
CHAIR
:
William H. Catherino, M.D., Ph.D.
SPEAKER
(S):
William H. Parker, M.D.
Elizabeth A. Stewart, M.D., Mayo Clinic
Description
Uterine leiomyomata have been identified in over 70% of hysterectomy specimens, with 20-50% of tumors causing
symptoms. The Agency for Healthcare Research and Quality reported approximately 613,000 total discharges in 2000 with a diagnosis of hysterectomy for leiomyomata. At a mean cost of approximately $14,000 per admission, that is a total of more than $8 billion per year.
There is also documented racial disparity in women diagnosed and treated for uterine leiomyomata. African American and Caribbean African women are 2-3 times more likely to undergo a hysterectomy for leiomyomata when compared with Caucasian or Hispanic women. The lifetime likelihood of hysterectomy for a woman of African descent approaches 22%, compared with 7-8% for Caucasian women. African American women presenting for myomectomy are younger and have more leiomyomata compared to their Caucasian counterparts.
Despite the impact of uterine leiomyomata on a societal and individual level, little is known about the etiology and optimal management. Current practice involves removal of the uterus and leiomyomata en toto, while best practice (both now and in the near future) provides for more targeted therapy.
Because there is significant controversy among providers as to the best options for medical or surgical intervention, gynecologists need up-to-date information on novel therapies for and advances in knowledge about leiomyoma. This course will provide participants with a clear understanding of the scope of the problem, cutting-edge, clinically relevant data for practitioners and patients, and the framework for future advances that should lead to standardized treatment and improved patient outcomes.
LEARNING OBJECTIVES
At the conclusion of this course, participants should be able to:
1. List the benefits and drawbacks of current therapy for uterine leiomyomata, as well as of promising therapies that will soon be available to the practitioner caring for women suffering from leiomyomata.
2. Identify the role that race plays in the development of leiomyomata in general, the symptoms associated with the
disease, and the outcomes of therapy.
3. Identify novel compounds that may provide therapeutic benefit to women suffering from leiomyomas.
4. Discuss the impact of symptomatic leiomyomata on fertility and pregnancy.
To purchase a downloadable PDF of the PG course syllabus or syllabi, click here.
symptoms. The Agency for Healthcare Research and Quality reported approximately 613,000 total discharges in 2000 with a diagnosis of hysterectomy for leiomyomata. At a mean cost of approximately $14,000 per admission, that is a total of more than $8 billion per year.
There is also documented racial disparity in women diagnosed and treated for uterine leiomyomata. African American and Caribbean African women are 2-3 times more likely to undergo a hysterectomy for leiomyomata when compared with Caucasian or Hispanic women. The lifetime likelihood of hysterectomy for a woman of African descent approaches 22%, compared with 7-8% for Caucasian women. African American women presenting for myomectomy are younger and have more leiomyomata compared to their Caucasian counterparts.
Despite the impact of uterine leiomyomata on a societal and individual level, little is known about the etiology and optimal management. Current practice involves removal of the uterus and leiomyomata en toto, while best practice (both now and in the near future) provides for more targeted therapy.
Because there is significant controversy among providers as to the best options for medical or surgical intervention, gynecologists need up-to-date information on novel therapies for and advances in knowledge about leiomyoma. This course will provide participants with a clear understanding of the scope of the problem, cutting-edge, clinically relevant data for practitioners and patients, and the framework for future advances that should lead to standardized treatment and improved patient outcomes.
LEARNING OBJECTIVES
At the conclusion of this course, participants should be able to:
1. List the benefits and drawbacks of current therapy for uterine leiomyomata, as well as of promising therapies that will soon be available to the practitioner caring for women suffering from leiomyomata.
2. Identify the role that race plays in the development of leiomyomata in general, the symptoms associated with the
disease, and the outcomes of therapy.
3. Identify novel compounds that may provide therapeutic benefit to women suffering from leiomyomas.
4. Discuss the impact of symptomatic leiomyomata on fertility and pregnancy.
To purchase a downloadable PDF of the PG course syllabus or syllabi, click here.
This session is a part of: